黑色素瘤患者中神经元自身抗体与认知功能障碍相关
在柏林夏里特医学院皮肤科连续招募157例黑色素瘤患者检测神经元自身抗体,22.3%阳性;对排除混杂因素后的84例进行神经心理评估,抗体阳性者认知障碍风险约为阴性者的3.1倍,且抗NMDAR抗体滴度越高认知损害越重。
要点
- 157例黑色素瘤患者中22.3%检出神经元自身抗体,以IgA/IgM型抗NMDAR抗体最常见。
- 评估的84例中36.9%存在认知障碍,抗体阳性者占57.1%、阴性者占30.2%,OR=3.1(95%CI 1.1–8.6,P=0.037)。
- 抗体阳性者整体认知z值-0.38±0.69,低于抗体阴性者的0.00±0.56(P=0.014)。
核心结论
- 大量黑色素瘤患者携带神经元自身抗体,且与累及记忆、注意力和执行功能的显著认知障碍相关。
- 神经元自身抗体可能是癌症相关认知障碍的病理生理因素和潜在生物标志物。
研究设计与样本
- 在柏林夏里特医学院皮肤科连续招募157例黑色素瘤患者(中位年龄63岁)检测神经元自身抗体。
- 排除脑转移、相关药物和神经系统疾病等混杂因素后,对84例患者进行综合神经心理评估。
主要发现
- 22.3%的黑色素瘤患者检出神经元自身抗体,最常见的为IgA/IgM抗NMDAR抗体。
- 按国际认知与癌症工作组标准,36.9%存在认知障碍;抗体阳性者57.1% vs 抗体阴性者30.2%,OR=3.1(95%CI 1.1–8.6;P=0.037)。
- 抗NMDAR抗体患者中,认知损害随抗体滴度升高而加重(P=0.007)。
- 抗体阳性者整体认知z值-0.38±0.69 vs 抗体阴性者0.00±0.56(P=0.014),记忆、注意力和执行功能测试亦显著受损。
- 多因素线性回归中,自身抗体为认知障碍的独立危险因素(B=-0.282;95%CI -0.492至-0.071;P=0.009);抗体血清阳性与免疫检查点抑制剂治疗及自身免疫性疾病史相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cancer-related cognitive impairment is an important complication in cancer patients, yet the underlying mechanisms remain unknown. Over the last decade, the field of paraneoplastic neurological syndromes has been dramatically changed by the discovery of new neuronal autoantibodies, some of them associated with cognitive impairment. We aimed to assess the prevalence of neuronal autoantibodies in melanoma patients and their association with neurological and cognitive dysfunction. PATIENTS AND METHODS: A total of 157 consecutive melanoma patients with a median age of 63 years were recruited at the Department of Dermatology, Charité-Universitätsmedizin Berlin and tested for neuronal autoantibodies. A comprehensive neuropsychological assessment was carried out in a selected subgroup of 84 patients after exclusion of patients with confounding factors for a cognitive dysfunction, including brain metastases, relevant medication, and neurological disorders. RESULTS: Neuronal autoantibodies were found in 22.3% of melanoma patients. The most frequent antibodies were IgA/IgM anti-NMDAR antibodies. Applying the International Cognition and Cancer Task Force criteria, 36.9% had cognitive impairment, however, with a threefold higher odds in antibody-positive compared with antibody-negative patients (57.1% versus 30.2%, OR = 3.1, 95% CI: 1.1 to 8.6; P = 0.037). In patients with anti-NMDAR antibodies, this impairment increased with higher antibody titers (P = 0.007). Antibody-positive patients had a significantly impaired overall cognitive performance (z-value: -0.38 ± 0.69 versus 0.00 ± 0.56; P = 0.014) as well as significant impairments in tests of memory, attention, and executive function. In a multiple linear regression analysis, autoantibodies were an independent risk factor for cognitive impairment (B = -0.282; 95% CI: -0.492 to -0.071; P = 0.009). Autoantibody seropositivity was associated with immune checkpoint inhibitor treatment and a history of autoimmune diseases. CONCLUSIONS: A large number of melanoma patients harbor neuronal autoantibodies that are associated with significant cognitive impairment affecting memory, attention, and executive function. Neuronal autoantibodies might represent a pathophysiological factor and possible biomarker in the development of cancer-related cognitive impairment.
引用
- Bartels F, Strönisch T, Farmer K, et al. Neuronal autoantibodies associated with cognitive impairment in melanoma patients. Ann Oncol. 2019. PMID: 30840061. doi:10.1093/annonc/mdz083
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。